Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Xpovio (Selinexor),XP1001,2022,USA,MDV,350,72,48,52,27.5,35,65,12,15,30,40,15,55,25,15,5,20,35,45,22,8,5,10,7,18,42,58,Cyclophosphamide + Doxorubicin,Docetaxel + Carboplatin,AC-T,Taxol,15,20,18,30,60,45,15,45,40,60,2
Xpovio (Selinexor),XP1002,2023,Canada,Claim Database,420,75,51,49,28.1,38,62,10,12,28,42,18,52,28,14,6,18,33,49,24,9,6,11,8,20,40,60,FEC,Taxotere + Cyclophosphamide,TC,CMF,17,18,20,32,62,47,12,48,40,62,2.5
Xpovio (Selinexor),XP1003,2023,UK,MDV,280,70,45,55,26.8,40,70,15,18,32,35,15,60,20,15,5,22,38,40,20,7,4,9,6,15,45,55,EC,CMF,Docetaxel,Cyclophosphamide,13,22,15,28,58,42,18,42,40,58,1.8
